EUCTR2008-005232-33-DE进行中（未招募）1 期
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Patient has given written informed consent before any trial-related activity is performed.
- •2. Has a confirmed prostate cancer in which this type of treatment is needed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous treatment for prostate cancer
- •2. Previous trans-urethral resection of the prostate
- •3. Patients who are lymph node positive or have other metastatic disease
- •4. Use of urethral catheter
- •5. Current treatment with a 5-alpha reductase inhibitor or a-adrenoceptor antagonist.
- •6. History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
- •7. Hypersensitivity towards any component of the investigational product
- •8. Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.
- •9. Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)
- •10. Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.
研究者
相似试验
进行中（未招募）
1 期
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1Level: PTClassification code 10060862Term: Prostate cancerProstate CancerEUCTR2008-005232-33-FRFerring Pharmaceuticals A/S240
进行中（未招募）
1 期
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1 Level: PT Classification code 10060862 Term: Prostate cancerProstate CancerEUCTR2008-005232-33-GBFerring Pharmaceuticals A/S240
进行中（未招募）
不适用
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1Level: PTClassification code 10060862Term: Prostate cancerProstate CancerEUCTR2008-005232-33-NLFerring Pharmaceuticals A/S240
进行中（未招募）
不适用
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1Level: PTClassification code 10060862Term: Prostate cancerProstate CancerEUCTR2008-005232-33-GRFerring Pharmaceuticals A/S240
进行中（未招募）
不适用
A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of volume reduction of the prostate in patients with prostate cancer being candidates for medical castration - FE200486 CS31MedDRA version: 9.1Level: PTClassification code 10060862Term: Prostate cancerProstate cancerEUCTR2008-008604-40-PTFerring Pharmaceuticals A/S180